Latest News

Today’s top news highlights: Primary care practices struggle, Americans split on COVID-19 vaccine

Publish date: May 27, 2020

 

Biologic approved for atopic dermatitis

The Food and Drug Administration approved dupilumab for children aged 6-11 years with moderate to severe atopic dermatitis. This is the first biologic approved for atopic dermatitis in this age group. The new indication is for children whose disease is not adequately controlled with topical prescription therapies. READ MORE.

For more on COVID-19, visit our Resource Center. All of our latest news is available on MDedge.com.

Pages

Recommended Reading

Today’s top news highlights: Remdesivir data dive, FDA approves contraceptive gel
MDedge Hematology and Oncology
Immunotherapy, steroids had positive outcomes in COVID-19–associated multisystem inflammatory syndrome
MDedge Hematology and Oncology
More evidence hydroxychloroquine is ineffective, harmful in COVID-19
MDedge Hematology and Oncology
COVID-19: Psychiatrists assess geriatric harm from social distancing
MDedge Hematology and Oncology
Severe disease not uncommon in children hospitalized with COVID-19
MDedge Hematology and Oncology
Can you catch COVID-19 through your eyes?
MDedge Hematology and Oncology
Seek safe strategies to diagnose gestational diabetes during pandemic
MDedge Hematology and Oncology
Domestic violence amid COVID-19: Helping your patients from afar
MDedge Hematology and Oncology
Half of Americans would get COVID-19 vaccine, poll shows
MDedge Hematology and Oncology
COVID-19 complicates prescribing for children with inflammatory skin disease
MDedge Hematology and Oncology